Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies

Chemoimmunotherapy with rituximab (R-chemo) or obinutuzumab (G-chemo) is standard of care for patients with previously untreated symptomatic or high-tumor-burden follicular lymphoma. Median progression-free survival (PFS) with R-chemo plus R maintenance exceeds 10 years, and G-chemo plus G maintenan...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodgers, Thomas D., Casulo, Carla, Boissard, Frederic, Launonen, Aino, Parreira, Joana, Cartron, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594248/
https://www.ncbi.nlm.nih.gov/pubmed/34319556
http://dx.doi.org/10.1007/s40487-021-00161-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594248/
https://www.ncbi.nlm.nih.gov/pubmed/34319556
http://dx.doi.org/10.1007/s40487-021-00161-5

Ejemplares similares